In vitro diagnostics company T2 Biosystems, Inc. is making waves in the medical industry with its cutting-edge diagnostic products and candidates. Based in both the United States and internationally, the company's advanced technology focuses on the detection of pathogens, biomarkers, and abnormalities in various patient sample types, including urine and cerebral spinal fluid. Its diverse product range includes the T2Dx Instrument - a versatile bench-top device that performs a range of diagnostic tests - and the T2Candida panel, a direct-from-blood test that rapidly identifies blood stream infections causing sepsis and candidemia. Other products include the T2Bacteria panel for detecting bacterial pathogens associated with sepsis, the T2Resistance panel for identifying carbapenem resistance genes, and the T2SARS-CoV-2 panel that detects the SARS-CoV-2 virus causing COVID-19. The company is also working on developing the T2Biothreat panel, a comprehensive sepsis panel for identifying bloodstream infections caused by bacterial and Candida species and antibiotic-resistant markers, the T2Cauris panel for direct detection of the emerging superbug Candida auris, and the T2Lyme panel for identifying the bacteria that cause Lyme disease. Founded in 2006 and headquartered in Lexington, Massachusetts, T2 Biosystems is a company to watch in the exciting and constantly-evolving field of medical diagnostics.